Ratings Moves: MGM,...
Health Care: Drugs
Celgene Corporation (CELG: NASDAQ)
$124.74 1.30 | 1.05%
05/23/13 - 02:56 PM ET
Company Balance Sheet
| Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
| Assets | ||||
|---|---|---|---|---|
| Cash and Equivalents | 2.09B | 1.86B | 1.35B | 1.10B |
| Receivables | 960.52M | 945.53M | 706.43M | 438.62M |
| Inventories | 259.50M | 189.57M | 260.13M | 100.68M |
| Other Current Assets | 320.21M | 453.22M | 623.56M | 258.94M |
| Total Current Assets | 5.53B | 4.35B | 4.34B | 3.84B |
| Property, Plant & Equipment, Gross | 919.14M | 766.44M | 697.62M | 437.47M |
| Accumulated Depreciation & Depletion | 340.78M | 260.40M | 187.71M | 139.68M |
| Property, Plant & Equipment, Net | 578.36M | 506.04M | 509.92M | 297.79M |
| Intangibles | 3.10B | 2.84B | 3.25B | 349.54M |
| Other Non-Current Assets | 479.08M | 414.72M | 179.20M | 319.06M |
| Total Non-Current Assets | 6.20B | 5.65B | 5.83B | 1.54B |
| Liabilities & Shareholder Equity | ||||
| Total Assets | 11.73B | 10.01B | 10.18B | 5.39B |
| Accounts Payable | 145.65M | 121.52M | 94.46M | 36.63M |
| Short Term Debt | 308.46M | 526.68M | 0.00 | 0.00 |
| Other Current Liabilities | 443.14M | 175.71M | 367.22M | 140.64M |
| Total Current Liabilities | 1.69B | 1.54B | 1.07B | 494.70M |
| Long Term Debt | 2.77B | 1.28B | 1.25B | 0.00 |
| Deferred Income Taxes | 1.02B | 775.02M | 882.87M | 0.00 |
| Other Non-Current Liabilities | 559.90M | 902.60M | 980.85M | 500.00M |
| Minority Interest | 0.00 | -694.00K | -320.00K | 0.00 |
| Total Non-Current Liabilities | 4.35B | 2.95B | 3.12B | 500.00M |
| Total Liabilities | 6.04B | 4.49B | 4.19B | 994.70M |
| Preferred Stock Equity | 0.00 | 0.00 | 0.00 | 0.00 |
| Common Stock Equity | 5.69B | 5.51B | 5.98B | 4.39B |
| Common Par | 4.98M | 4.87M | 4.82M | 4.68M |
| Additional Paid In Capital | 7.54B | 6.76B | 6.35B | 5.47B |
| Cumulative Translation Adjustment | 0.00 | 0.00 | 0.00 | 0.00 |
| Retained Earnings | 3.02B | 1.57B | 248.27M | -632.25M |
| Treasury Stock | -4.82B | -2.76B | -545.59M | -362.52M |
| Other Equity Adjustments | -49.75M | -62.34M | -73.77M | -89.42M |
| Total Capitalization | 8.47B | 6.79B | 7.23B | 4.39B |
| Total Equity | 5.69B | 5.51B | 5.98B | 4.39B |
| Total Liabilities & Stock Equity | 11.73B | 10.01B | 10.18B | 5.39B |
| Total Common Shares Outstanding | 419.75M | 437.49M | 470.39M | 459.29M |
| Preferred Shares | 0.00 | 0.00 | 0.00 | 0.00 |
| Treasury Shares | 78.68M | 49.89M | 11.78M | 8.34M |
| Basic Weighted Shares Outstanding | 430.93M | 455.35M | 462.30M | 459.30M |
| Diluted Weighted Shares Outstanding | 440.80M | 462.75M | 469.52M | 467.35M |
| Number of Employees | 4700 | 4460 | 4182 | 2813 |
| Number of Part-Time Employees | 0 | 0 | 0 | 0 |
Portfolios with CELG
- Portfolio NameUser Type
- Userdennis all star
- Userportfolio 1.1
- UserCraigMcIlquham
- User4 Overvalued Biotechs
- ProRay Dalio - Bridgewater Ass...
- ProBill Miller - Legg Mason Ca...
- ContributorStocks Rising On Unusual Vo...
- UserTest Portfolio
- UserMike Fatah's Mega Stock Por...
- User2012 Allocation
Latest CELG Headlines from TheStreet
- 5 Stocks Raising The Drugs Industry Higher 05.23.13 | 01:05 pm
- Cramer's 'Mad Money' Recap: Ignore the Fed 05.22.13 | 07:05 pm
- Cramer: A Pile of Simply Horrendous Advice 05.20.13 | 11:05 am
- Celgene Corporation (CELG): Today's Featured Health Care Winner 05.17.13 | 05:05 pm
- AGN, LLY, BIIB, CELG And AMGN, Pushing Health Care Sector Downward 05.16.13 | 01:05 pm
- Cramer's 'Mad Money' Recap: Stick With What Works 05.14.13 | 08:05 pm
- Celgene Stock Hits New 52-Week High (CELG) 05.13.13 | 10:05 am
- Celgene Corporation (CELG): Today's Featured Drugs Winner 05.10.13 | 05:05 pm
- Cramer: Biotech Makes a Comeback 05.10.13 | 04:05 pm
- 5 Stocks Advancing The Drugs Industry 05.07.13 | 01:05 pm
Press Releases for CELG
- Celgene Corporation To Webcast At Two Upcoming Investor Conferences And The American Academy Of Dermatology Annual Meeting - Business Wire 02.28.13 | 08:02 am
- Celgene Announces $600 Million Accelerated Share Repurchase Program - Business Wire 02.20.13 | 08:02 am
- Celgene Provides REVLIMID® Regulatory Update - Business Wire 02.11.13 | 07:02 am
- POMALYST(R) Brand Therapy (Photo: Business Wire) - Business Wire 02.08.13 | 03:02 pm
- Celgene Corporation To Webcast At Upcoming Investor Conferences - Business Wire 02.04.13 | 08:02 am
- Celgene Reports Strong Fourth Quarter And Full Year 2012 Operating And Financial Results - Business Wire 01.24.13 | 07:01 am
- The True Effect: Positive Findings - Research Report On Celgene Corporation And Gilead Sciences, Inc. - PR Newswire 01.23.13 | 08:01 am
- ABRAXANE® Plus Gemcitabine Demonstrates Significant Survival Advantage In Phase III Study Of Patients With Advanced Pancreatic Cancer - Business Wire 01.22.13 | 06:01 pm
- Celgene Corporation Announces Financial Outlook And Preliminary 2012 Results - Business Wire 01.07.13 | 11:01 am
- Celgene Corporation To Present At The 31st Annual J.P. Morgan Healthcare Conference - Business Wire 12.21.12 | 08:12 am
Partner Headlines for CELG
- Alkermes Leaps On Study Results, May Offer New Entry - Investor's Business Daily 04.17.13 | 05:04 pm
- Big Cap Leaders Slide But Show Little Technical Damage - Investor's Business Daily 04.15.13 | 07:04 pm
- Pockets of Strength In Top Groups, Few Leaders Basing - Investor's Business Daily 04.15.13 | 06:04 pm
- Stocks On The Move Table Identifies Emerging Leaders - Investor's Business Daily 04.10.13 | 05:04 pm
- How The IBD 50 Can Help Investors Find Winning Stocks - Investor's Business Daily 04.05.13 | 04:04 pm
- Stocks Open Sharply Lower After Employment Report - Investor's Business Daily 04.05.13 | 10:04 am
- Benzinga's Top Upgrades - Benzinga 04.05.13 | 08:04 am
- Can New Psoriasis Drugs Scratch Investors' Itch? - Investor's Business Daily 04.04.13 | 01:04 pm
- Top Funds' New Buys: Lumber Liquidators, Celgene - Investor's Business Daily 04.02.13 | 06:04 pm
- U.S. Mutual Funds Up 10% In Q1; Managers' Top Buys - Investor's Business Daily 04.02.13 | 06:04 pm
